THE SUBPOPULATION FEATURES OF DENDRITIC CELLS AS A POTENTIAL BIOMARKER OF EARLY RHEUMATOID ARTHRITIS

Maxim Korely, Yuliya Kurochkin, Nadezda Barashikhova, Vitaly Orelenchenko, Anna Akimova, Elena Lazagina, Mariya Surovtseva, Alexander Lykov, Olga Poveschenko. Research Institute of Clinical and Experimental Lymphmophy – branch of the Institute of Cytology and Genetics, Siberian Branch of the Russian Academy of Sciences, 2, Tymakova street, Novosibirsk, Russian Federation

Background: Dendritic cells (DCs) are professional antigen-presenting cells (APCs), which play important role in immune responses. DCs are a heterogeneous population and can be divided into groups: myeloid (mDCs) and plasmacytoid (pDCs). Furthermore, DCs are important in rheumatoid arthritis (RA) pathogenesis through antigen presentation and activation of autoreactive T-lymphocytes. As established the different subpopulation DCs can promote different immune reactions. That’s why, it may be possible to consider them as a potential target for the development of new target of the immunopathological disorders therapy.

Objectives: To investigate the subpopulations of peripheral blood DCs (myeloid and plasmacytoid) in patients with early RA as a predictor of responsivity to disease-modifying antirheumatic drugs (DMARDs) treatment.

Methods: Forty nine patients with early RA (duration of the disease up to 12 months) were included in the study. All patients fullfilled ACR/ EULAR criteria (2010) and received methotrexate, leflunomide, sulfasalazine or their combination. Forty three patients with osteoarthritis (OA) used as a control group. Analysis of the content of the B-lymphocytes, myeloid and plasmacytoid DCs, labeled by antibodies against surface markers, was carried out by flow cytometry. B-lymphocytes, subtypes of myeloid peripheral blood DCs were characterized by the following phenotypes: myeloid DCs (CD3-CD14-CD19-HLA-DR + CD11c + CD123-), plasmacytoid DCs (CD3-CD14-CD19-HLA-DR + CD11c+CD123 + ), B-lymphocytes (CD19 +). Analysis were performed before treatment and after 3 and 6 months.

Results: Patients with early RA are characterized by significant evaluation of the population of plasmacytoid DCs in comparison of patients with moderate stages of rheumatoid arthritis and osteoarthritis (3.8 vs 2.1 vs 1, p=0.0042). Furthermore, the difference was found in the number of cells with the phenotype B-lymphocytes: 7.95 * 10^6/l vs. 3.6* 10^6/l, respectively (p = 0.014). No significant differences were observed in the number of myeloid DCs. After 6 month of observation we detected reducing amount of plasmacytoid DCs (3.8 before treatment and 2.1 in 6 month, p=0.002) and B-cells that correlated with activity of disease.

Conclusion: The data obtained indicated that plasmacytoid DCs are predominant in patients with inflammatory arthritis especially in early RA and correlate with activity of disease that can be used as a predictor of good response on DMARDs treatment.

Disclosure of Interests: None declared


THE DIFFERENTIAL PRODUCTION OF REACTIVE OXYGEN SPECIES IN T CELL SUBSETS IN PERIPHERAL BLOOD OF RHEUMATOID ARTHRITIS PATIENTS

Ha-Reum Lee, Su-Jin Yoo, Jinhyun Kim, In Seol Yoo, Chan Kee Park, Seong Wook Kang. Chungnam National University College of Medicine, Department of Internal Medicine, Daejeon, Korea, Rep. of (South Korea)

Background: T cells play a regulatory role in rheumatoid arthritis (RA) through inducing the homeostasis maintenance and self-tolerance [1]. Specifically, the production and the oxidation mechanism of reactive oxygen species (ROS) were out of balance.

Objectives: The aim of the study was to compare ROS productions in T cell subset, which are helper T (TH) cell, cytotoxic T (TC) cell, T helper 17 (TH17) cell and regulatory T (Treg) cell in peripheral blood mononuclear cells (PBMC) of RA patients with RA activity.

Methods: Blood samples were collected from 30 RA patients and 10 healthy adult volunteers under IRB approval. RA activity was divided according to the DAS28 parameter. PBMC cells were obtained from the whole blood using lymphocyte separation medium density gradient centrifugation. For separation between the live and dead cell populations, PBMC was stained with Live/Dead stain dye. After PBS washing, cells were incubated with antibodies for CD3, CD4, CD8, and CD25. Following fixation and permeabilization, and further stained with antibodies for FoxP3 and IL-17A. For ROS staining, CellRox and MitoSox were used.

Results: The frequency of TH cell was increased and that of TC cell was decreased in the peripheral blood of RA patients. TH17 and Treg cell population were significantly increased more than about 2-3 folds in active and inactive RA than healthy control. When the whole of cellular ROS production was measured, only Treg cell population was significantly increased in RA than control. Although ROS level was steadily increased with RA activity, there was a slight decline in severe RA compared to moderate and low RA. This difference is lager in mitochondrial specific ROS than total cellular ROS. The mitochondrial complex inhibitor reduced Treg cell frequency in PBMC from RA patients.

Conclusion: Treg is the most sensitive to ROS production among T cell subsets in RA. These findings provide a novel approach to regulate Treg function in RA through mitochondrial metabolism related ROS production.

REFERENCES

Disclosure of Interests: None declared


TRANSCRIPTOMIC PROFILING OF THE MICROENVIRONMENT DRIVEN RE-SHAPING OF PATHOGENIC CIRCULATORY AND SYNOVIAL HLA-DR+ CD4 T SUBSETS IN ACTIVE JUVENILE IDIOPATHIC ARTHRITIC PATIENTS

Jing-Van Leong1, Pavansish Kumar1, Phyllis Chen1, Joo Guan Yeo1, Camillus Chu2, Sharifah Nur Hazirah1, Thaschawee Arkachaisri1,2, Alessandro Consolato1, Marco Gattorno3, Alberto Martini3, Salvatore Albani1.

1Translational Immunology Institute, SingHealth-Duke-NUS Academic Medical Centre, Singapore, Singapore; 2KK Women’s and Children’s Hospital, Singapore, Singapore; 3Second Paediatric Division, University of Genoa and G Gaslini Institute, Genova, Italy

Background: We have previously identified two pathogenic circulatory CD4 subsets in both T-eff (CPLs), and Treg (iaTreg) compartments of JIA patients that are HLA-DR+, antigen experienced, pro-inflammatory, correlating positively with disease activity and possessing strong synovial TCR sequence coverage. Despite being two functionally discordant T cell subsets (Teff/Treg), their immuno-phenotype and association with clinical fate suggests that these subsets may originate from a common precursor.

Objective: We seek to understand how the microenvironment could potentially influence and drive these subsets (CPLs/iaTregs) towards their pathological state. In an attempt to elucidate the common pathological gene drivers, we decided to perform next-generation RNA sequencing on sorted CPLs/iaTregs and conventional T-eff/Treg counterparts in both circulation and synovium.

Methods: CPLs were sorted as CD3+ CD4+ CD14+ CD25+ (HDLR) CD25+CD127 low T cell gate, and iaTregs were sorted as CD3+ CD4+ CD14+ HDLR+ CD25+CD127 high T cell gate, and iaTregs were sorted as CD3+ CD4+ CD14+ HDLR+ CD25+CD127low T cell gate with FACs Aria II from n=16 active JIA PBMCs, n=8 paired JIA SFMCs, and n=8 healthy paediatric PBMCs. As a comparative control, similar HDLR+ counterparts were respectively sorted from the same patients. Sorted cells were lysed and extracted for RNA, and cDNA conversion/amplification were then carried out using SMART-seq v4. Libraries are prepared and multiplexed using Nextera XT DNA library preparation kit, and ran on the Illumina HiSeq High output platform.

Results: Comparative differential gene expression (DEG) analysis within the circulatory compartment indicate transcriptomic convergence between CPLs/iaTreg and divergence away from conventional T-eff/Treg pools. Circulatory CPLs/iaTregs exhibit (a) common pathway dysregulation in T cell signalling (IFN-g, PD1, CD28 costimulation), (b) restriction in TCR oligo- diversity, and (c) common transcription factor drivers (SPL1 and E2F1) within the gene regulatory network, suggesting a common driving source acting on these two disparate compartments.

To understand how this convergence originate, we compared CPLs/iaTreg and conventional T-eff/iaTreg subsets from (a) healthy circulatory PBMCs, (b) JIA circulatory PBMCs and (c) paired JIA synovium. There was a gradual increase in transcriptomic convergence between T-eff/CPLs, Treg/ iaTreg and CPLs/iaTreg across the spatial/disease continuum, that is paralleled by an antigenic convergence in shared TCR clonotypes in CPLs/
THE EFFECT OF DIMETHYL FUMARATE ON IMPACT OF TOCILIZUMAB ON IMMUNE PHENOTYPES

Myles Lewis1,3.

Negative (DN) (CD27 -IgD-) B cells, pre-plasmablasts (pre-PBs) (CD27 +, CD20low, CD38 -) and plasmablasts (PBs) (CD27 +, CD20 low, CD38 +).


Disclosure of Interests: Daniele Mauro: None declared, Felice Rivelles: None declared, Sotria Manou-Stathopoulou: None declared, Katriona Goldmann: None declared, Debashis Pyne: None declared, Francesco Ciccia Grant/research support from: MG has received unrestricted grants from Sobi and Novartis. Costantino Pitzalis Grant/research support from: CELGENE, PFIZER, Consultant for: UCB, NOVARTIS, CELGENE, PFIZER, Lilly, Lilly, JANSSEN, Speakers bureau: UCB, NOVARTIS, CELGENE, PFIZER, Lilly, JANSSEN, ROCHE, ABBOTT, Camillus Chua: None declared, Sharifah Nur Hazirah: None declared, Phyllis Chen: None declared, Joo Guan Yeo: None declared.

Background: The pathogenesis of large vessel vasculitis (LVV) such as Takayasu arteritis (TAK) and giant cell arteritis (GCA) consists of the imbalance between Th17 cells and Treg cells, which is associated with LVV. However, little is known about pathological immune cell subsets targeted by immunosuppressants and/or molecular-target therapy such as IL-6 blockade.

Objectives: The aim of this study was to assess the relationship between the phenotype of peripheral immune cells with clinical manifestations and responsiveness to the treatment in patients with LVV.

Methods: Peripheral blood mononuclear cells were obtained from 22 patients with active LVV (TAK 7, GCA 15) and 19 healthy donors (HD). All patients were treated with high dose glucocorticoid (GC). The study included the patients treated with immunosuppressive agents such as azathioprine and methotrexate (n=8) or with anti-IL-6 receptor antibody tocilizumab (n=7). The blood samples were taken at baseline and week 24 after treatment. The peripheral immune cell subset was defined based on comprehensive B-color flow cytometric analysis for human immune system termed “the Human Immunology Project” by NIH and FOCSIS, and the correlation with clinical characteristics and responsiveness to the therapies were evaluated.

Results: The proportion of CD3+CD4+CXCR3+CCL6+CD38+HLA-DR+ activated Th17 cells and CD3+CD4+CXCX5+1COS+CDB38- activated Th cells in patients with TAK and that of activated Th17 cells and CD19+CD20+CD7+IgD+ double negative effector B cells in patients with GCA were significantly higher than those in HD. At baseline, the frequency of activated Th cells showed positive correlation and that of CD4+CCR4+CD25+CD122+ T regulatory (Treg) cells showed negative correlation with disease activity scores such as Indian Takayasu Activity Index (ITAS)2010 [3] and ITAS.A (CRP) in both TAK and GCA. The immunosuppressive therapy improved the disease activity in all patients. The frequency of activated Th cells was reduced by 24-week treatment with high dose GC and immunosuppressants in TAK and GCA. However, the frequency of Th17 cells was not changed by those treatments. Of note, tocilizumab decreased the proportion of activated Th17 cells and increased the proportion of Treg cells in both TAK and GCA.

Conclusion: The results indicated that the abnormal T cell differentiation correlated with disease activity of LVV. Although T cell activation was improved, Th17 cell activation was not changed by the conventional immunosuppressive agents. By contrast, tocilizumab reduced Th17 cells and increased Treg cells, indicating that IL-6 blockade may correct the impaired balance of Th17 and Treg cells in patients with LVV.